Adverum Biotechnologies (ADVM), a clinical-stage gene therapy company, discovers and develops novel medicines for patients suffering from rare and ocular diseases.
ADVM's pipeline includes product candidates, which are used for the treatment of wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development for wAMD diseases; and ADVM-043 for the treatment of A1AT. ADVM is also developing ADVM-053 to treat hereditary angioedema; and other product candidates that comprise ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis.
It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.
The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
July 19, 2019
RegMed Investors’ (RMi) closing bell: expiration of options amplified the sector’s selloff
July 19, 2019
RegMed Investors’ (RMi) pre-open: the upside is heading to be overbought
July 18, 2019
RegMed Investors’ (RMi) closing bell: wow, another sustaining session
July 17, 2019
RegMed Investors’ (RMi) closing bell: lucky, lucky the sector rose
July 16, 2019
RegMed Investors’ (RMi) closing bell: Expectations are low in share pricing
July 12, 2019
RegMed Investors’ (RMi) closing bell: the upside and downside pricing was lean
July 11, 2019
RegMed Investors’ (RMi) closing bell: Insight about share pricing is about understanding perception
July 11, 2019
RegMed Investors’ (RMi) pre-open: run sector run
July 10, 2019
RegMed Investors’ (RMi) closing bell: the sector follows the markets
July 10, 2019
RegMed Investors’ (RMi) pre-open: fed news is today’s med or not
45 companies, 1 interpreter!
Insight, foresight and recommendation
Adverum Biotechnologies (ADVM - January '18 opened at $3.65 rolled up to $7.70 on February '18. After a $69 M offering of 10.22 M shares priced at $6.75 financing ... it's all about milestones and waiting for the news of catalysts.
hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.